kbet99
In a rapidly evolving tech landscape, Oracle Corporation (NYSE:ORCL) finds itself at a pivotal juncture against a backdrop of thriving AI-related stocks. Despite a whirlwind of activity in the realm of AI investments, Oracle’s position remains intriguing amidst varying analyst insights. CJ Muse, an analyst at Cantor Fitzgerald, recently commented on the novel nature of AI investments, highlighting a significant departure from typical tech cycles. He noted major tech firms are channeling billions into AI, and yet they’re managing to generate substantial free cash flow. Muse emphasizes that this investment cycle is critical as companies push towards achieving artificial general intelligence (AGI), requiring advanced computing power to enhance AI reasoning capabilities. As various AI stocks garner attention due to positive analyst ratings and noteworthy developments, Oracle’s performance draws mixed reviews. Monness, Crespi, Hardt analysts recently shifted their stance on ORCL to a “Sell” rating , citing that its stock price may have outstripped its value compared to historical benchmarks. Despite a strong showing fueled by generative AI trends, concerns about Oracle’s increased capital expenditure plans for fiscal 2025 linger, seen as possibly unsustainable. While Oracle continues to make strides in cloud infrastructure, bolstered by strategic partnerships like the one with Amazon, the firm faces stiff competition from industry giants in the public cloud space. Despite these challenges, Oracle ranks 7th among promptly buzzing AI stocks due to its continued innovation and market presence. For those eyeing promising AI opportunities, exploring under-the-radar stocks might offer a chance for more substantial returns over a shorter period than established names like Oracle, as noted in recent financial analyses. Is Oracle Navigating the AI Wave Successfully? Unveiling Insights and Predictions Oracle Corporation is at a critical juncture amidst a flourishing landscape of AI-related investments, with varied insights from analysts marking its trajectory. As the tech giant makes headway in the AI domain, let’s explore some fresh perspectives and critical elements that are shaping its journey. Market Insights and Analysis In the rapidly advancing realm of artificial intelligence, Oracle’s strategic positioning is under scrutiny. While Oracle is making significant inroads in cloud infrastructure and AI, its approach has drawn mixed reviews from analysts. In particular, there is debate about whether Oracle’s market value has exceeded its fundamental worth, a concern accentuated by Monness, Crespi, Hardt analysts’ recent “Sell” recommendation. Pros and Cons of Oracle’s AI Strategy # Pros 1. Cloud Expansion : Oracle is enhancing its cloud-based offerings, a critical growth area in the era of digital transformation. 2. Strategic Partnerships : Collaborations with major firms, such as Amazon, highlight Oracle’s efforts to stay competitive. # Cons 1. Valuation Concerns : Analysts have raised concerns about Oracle’s stock being possibly overvalued, given historical benchmarks. 2. Sustainability of Capital Expenditures : Increased spending in fiscal 2025 raises questions about the long-term sustainability of its investments. AI Investment Trends and Innovations Oracle is navigating an AI investment cycle marked by substantial enhancements in computing power. The broader tech industry is pushing toward achieving artificial general intelligence, and Oracle’s efforts are pivotal in this ambition. However, while Oracle is among the top AI stocks, other emerging companies are capturing attention due to potentially higher short-term returns. Predictions and Future Directions Moving forward, analysts predict Oracle will face stiff competition from leading cloud providers. However, its continuous investment in AI and infrastructure could bolster its position in the market. As AI becomes more ingrained in various industries, Oracle’s efforts in cultivating strategic partnerships and enhancing its offerings may prove influential. Final Thoughts Oracle’s journey through the AI landscape is emblematic of both the challenges and opportunities presented to established tech firms. Staying competitive requires balancing innovation with sustainable growth strategies. As the company navigates this pivotal period, stakeholders and investors will need to closely monitor these dynamics to fully leverage Oracle’s potential in the evolving tech market. For more information on Oracle and its technological advancements, visit the Oracle website .
Dollar gains amid escalating geopolitical tensions
has ridden the generative AI boom to record-breaking revenues and profits over the past two years, and while it remains well ahead of its competitors, the company is facing growing pressure - not only from rival but also from hyperscalers which have traditionally relied on Nvidia GPUs but are now looking to reduce their dependence on its hardware. As notes, “Nvidia’s biggest problem is that its biggest customers have massive enough IT expenditures that they can afford to compete with Nvidia and AMD and design their own XPUs for serial and parallel computing. And when they do so, it is chip design and manufacturing houses Broadcom and Marvell, who have vast expertise running chippery through the foundries of Taiwan Semiconductor Manufacturing Co, who will be benefiting.” In its most , Hock Tan, President and CEO of Broadcom, told investors, “Specific hyperscalers have begun their respective journeys to develop their own custom AI accelerators or XPUs, as well as network these XPUs with open and scalable Ethernet connectivity. As you know, we currently have three hyper-scale customers who have developed their own multi-generational AI XPU roadmap to be deployed at varying rates over the next three years. In 2027, we believe each of them plans to deploy one million XPU clusters across a single fabric.” Gaining its fair share Without naming specific companies, Tan added, “To compound this, we have been selected by two additional hyperscalers and are in advanced development for their own next-generation AI XPUs.” It is widely believed that Broadcom is working with and Meta, and as we previously reported, with and on custom AI chips. is also thought to be developing its first artificial intelligence server chip, codenamed “Baltra,” with Broadcom providing the advanced networking technologies essential for AI processing. During the Q&A portion of the earnings call, when Tan was asked about market share, he responded, “All we are going to do is gain our fair share. We're just very well positioned today, having the best technology, very relevant in this space. We have, by far, one of the best combination technologies out there to do XPUs and to connect those XPUs. The silicon technology that enables it, we have it here in Broadcom by the boatloads, which is why we are very well positioned with these three customers of ours.”
NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering of $300.0 million of the Company’s ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), and, to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase Ordinary Shares (“Pre-Funded Warrants,” and such offering, the “Offering”). All Ordinary Shares and Pre-Funded Warrants to be sold in the proposed Offering will be sold by the Company. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of Ordinary Shares, less underwriting discounts and commissions. The proposed Offering is subject to market and other conditions and there can be no assurance as to whether or when the proposed Offering may be completed, or as to the actual size or terms of the proposed Offering. Jefferies, Goldman Sachs & Co., Leerink Partners, TD Cowen, Guggenheim Securities and William Blair are acting as joint book-running managers for the proposed Offering. The proposed Offering will be made pursuant to a registration statement on Form S-3, including a base prospectus, that was initially declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on July 12, 2024. The proposed Offering will be made only by means of a prospectus supplement and an accompanying prospectus, which will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov . A copy of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com ; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at Prospectus-ny@ny.email.gs.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40 th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com ; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, or by telephone at (855) 495-9846, or by email at TD.ECM_Prospectus@tdsecurities.com ; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com ; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by telephone at (800) 621-0687, or by email at prospectus@williamblair.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well-tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well-tolerated. Forward-Looking Statements Certain statements included in this document that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the consummation of the proposed Offering as well as the timing and size of the proposed Offering and the grant to the underwriters of the option to purchase additional Ordinary Shares. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the approval of the Company’s product candidate and the timing of expected regulatory and business milestones, including potential commercialization; ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive product candidates; ability to obtain sufficient supply of materials; global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflicts; the effects of competition on the Company’s future business; and those factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as supplemented by other documents filed by the Company with the SEC. Additional risks related to the Company’s business include, but are not limited to: uncertainty regarding outcomes of the Company’s ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidate; risks associated with the Company’s efforts to commercialize a product candidate; the Company’s ability to negotiate and enter into definitive agreements on favorable terms, if at all; the impact of competing product candidates on the Company’s business; intellectual property related claims; the Company’s ability to attract and retain qualified personnel; and the Company’s ability to continue to source the raw materials for its product candidate. If any of these risks materialize or the Company’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company’s expectations, plans, or forecasts of future events and views as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. The Company anticipates that subsequent events and developments may cause the Company’s assessments to change. These forward-looking statements should not be relied upon as representing the Company’s assessment as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither the Company nor any of its affiliates undertakes any obligation to update these forward-looking statements, except as may be required by law. Company Contact Matthew Philippe P: 1-917-882-7512 matthew.philippe@newamsterdampharma.com Media Contact Spectrum Science on behalf of NewAmsterdam Pharma Jaryd Leady P:1-856-803-7855 jleady@spectrumscience.com Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 austin.murtagh@precisionaq.comBoxing Day shopper footfall was down 7.9% from last year across all UK retail destinations up until 5pm, MRI Software’s OnLocation Footfall Index found. However, this year’s data had been compared with an unusual spike in footfall as 2023 was the first “proper Christmas” period without Covid-19 pandemic restrictions, an analyst at the retail technology company said. It found £4.6 billion will be spent overall on the festive sales. Before the pandemic the number of Boxing Day shoppers on the streets had been declining year on year. The last uplift recorded by MRI was in 2015. Jenni Matthews, marketing and insights director at MRI Software, told the PA news agency: “We’ve got to bear in mind that (last year) was our first proper Christmas without any (Covid-19) restrictions or limitations. “Figures have come out that things have stabilised, we’re almost back to what we saw pre-pandemic.” There were year-on-year declines in footfall anywhere between 5% and 12% before Covid-19 restrictions, she said. MRI found 12% fewer people were out shopping on Boxing Day in 2019 than in 2018, and there were 3% fewer in 2018 than in 2017, Ms Matthews added. She said: “It’s the shift to online shopping, it’s the convenience, you’ve got the family days that take place on Christmas Day and Boxing Day.” People are also increasingly stocking-up before Christmas, Ms Matthews said, and MRI found an 18% increase in footfall at all UK retail destinations on Christmas Eve this year compared with 2023. Ms Matthews said: “We see the shops are full of people all the way up to Christmas Eve, so they’ve probably got a couple of good days of food, goodies, everything that they need, and they don’t really need to go out again until later on in that week. “We did see that big boost on Christmas Eve. It looks like shoppers may have concentrated much of their spending in that pre-Christmas rush.” Many online sales kicked off between December 23 and the night of Christmas Day and “a lot of people would have grabbed those bargains from the comfort of their own home”, she said. She added: “I feel like it’s becoming more and more common that people are grabbing the bargains pre-Christmas.” Footfall is expected to rise on December 27 as people emerge from family visits and shops re-open, including Next, Marks and Spencer and John Lewis that all shut for Boxing Day. It will also be payday for some as it is the last Friday of the month. A study by Barclays Consumer Spend had forecast that shoppers would spend £236 each on average in the Boxing Day sales this year, but that the majority of purchases would be made online. Nearly half of respondents said the cost-of-living crisis will affect their post-Christmas shopping but the forecast average spend is still £50 more per person than it was before the pandemic, with some of that figure because of inflation, Barclays said. Amid the financial pressures, many people are planning to buy practical, perishable and essential items such as food and kitchenware. A total of 65% of shoppers are expecting to spend the majority of their sales budget online. Last year, Barclays found 63.9% of Boxing Day retail purchases were made online. However, a quarter of respondents aim to spend mostly in store – an 11% rise compared with last year. Karen Johnson, head of retail at Barclays, said: “Despite the ongoing cost-of-living pressures, it is encouraging to hear that consumers will be actively participating in the post-Christmas sales. “This year, we’re likely to see a shift towards practicality and sustainability, with more shoppers looking to bag bargains on kitchen appliances and second-hand goods.” Consumers choose in-store shopping largely because they enjoy the social aspect and touching items before they buy, Barclays said, adding that high streets and shopping centres are the most popular destinations.